|  | NE group (≤75 years); n = 738 | Missing data; n (%) | E group (> 75 years); n = 162 | Missing data; n (%) | p value |
---|---|---|---|---|---|---|
BMI; n (%) | < 30 | 496 (71.2%) | 41 (5.8%) | 128 (84.2%) | 10 (6.2%) | 0.001 |
≥30 | 201 (28.8%) | 24 (15.8%) | ||||
Gender; n (%) | Female | 344 (46.6%) | 0 (0%) | 73 (45.1%) | 0 (0%) | 0.729 |
Male | 394 (53.4%) | 89 (54.9%) | ||||
ASA; n (%) | I-II | 535 (76.0%) | 34 (4.6%) | 55 (35.7%) | 8 (4.9%) | 0.001 |
III-IV | 169 (24.0%) | 99 (64.3%) | ||||
CCI; n (%) | ≤5 | 603 (81.7%) | 0 (0%) | 47 (29.0%) | 0 (0%) | 0.001 |
> 5 | 135 (18.3%) | 115 (71.0%) | ||||
Ischemic heart disease; n (%) | Yes | 26 (3.5%) | 0 (0%) | 17 (10.5%) | 0 (0%) | 0.001 |
No | 712 (96.5%) | 145 (89.5%) | ||||
Diabetes mellitus; n (%) | Yes | 71 (9.6%) | 0 (0%) | 24 (14.8%) | 0 (0%) | 0.065 |
No | 667 (90.4%) | 138 (85.2%) | ||||
Cerebrovascular disease; n (%) | Yes | 18 (2.4%) | 0 (0%) | 9 (5.6%) | 0 (0%) | 0.043 |
No | 720 (97.6%) | 153 (94.4%) | ||||
Chronic kidney failure; n (%) | Yes | 9 (1.2%) | 0 (0%) | 4 (2.5%) | 0 (0%) | 0.267 |
No | 729 (98.8%) | 158 (97.5%) | ||||
Neoadjuvant treatment; n (%) | Yes | 163 (22.1%) | 0 (0%) | 29 (17.9%) | 0 (0%) | 0.289 |
No | 575 (77.9%) | 133 (82.1%) | ||||
Specimen length, cm (Mean ± SD) | 19 ± 8 | 22 (2.9%) | 21 ± 6 | 4 (2.4%) | 0.436 | |
Proximal end, cm (Mean ± SD) | 13 ± 7 | 27 (3.6%) | 13 ± 6 | 5 (3.0%) | 0.346 | |
Distal end, cm (Mean ± SD) | 4 ± 3 | 26 (3.5%) | 4 ± 4 | 5 (3.0%) | 0.109 | |
T; n (%) | T0–2 | 271 (36.7%) | 0 (0%) | 30 (18.5%) | 0 (0%) | 0.001 |
T3–4 | 467 (63.3%) | 132 (81.5%) | ||||
N; n (%) | N0 | 449 (61.8%) | 12 (1.6%) | 92 (57.1%) | 1 (0.6%) | 0.284 |
N+ | 277 (38.2%) | 69 (42.9%) | ||||
M; n (%) | M0 | 666 (90.2%) | 0 (0%) | 144 (88.9%) | 0 (0%) | 0.566 |
M1 | 72 (9.8%) | 18 (11.1%) | ||||
Stage; n (%) | 0 | 11 (1.5%) | 0 (0%) | 1 (0.6%) | 0 (0%) | 0.002 |
I | 203 (27.5%) | 23 (14.2%) | ||||
II | 205 (27.8%) | 64 (39.5%) | ||||
III | 246 (33.3%) | 56 (34.6%) | ||||
IV | 73 (9.9%) | 18 (1.1%) |